-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Neuroimmune diseases include multiple sclerosis, neuromyelitis optica spectrum diseases, acute disseminated encephalomyelitis, myasthenia gravis, Guillain-Barré syndrome and so on
.
Due to the abnormal activation of the immune system, this type of disease recognizes and attacks its own nervous tissues, resulting in a variety of complex neurological symptoms including blindness, paralysis, pain and paresthesias
.
A small number of patients will have difficulty breathing, even life-threatening
.
As the first cause of disability among young and middle-aged people, the course of this type of disease is protracted and repeated, causing heavy family and social burdens
.
As more and more immune-targeted drugs enter the market and medical insurance, the treatment of neuroimmune diseases ushered in the spring of our country
.
But we know that an important reference data for the country to formulate medical security policies and invest in disease research and development, the "morbidity rate" of diseases, that is, the basic question of how many people suffer from such diseases each year, is still a blank in our country, which has become a national issue.
Further use of these new drugs to better improve the barriers to these patients' medical services
.
On November 2, 2021, China published the incidence of Guillain-Barré syndrome in China for the first time in The Lancet Regional Health-Western Pacific (https:// /pii/S266660652100211X)
.
The article shows that the incidence of the disease in 31 provinces, autonomous regions and municipalities across the country is 0.
698 per 100,000, of which 0.
233 per 100,000 children and 0.
829 per 100,000 adults
.
Autoimmune diseases of the nervous system are relatively rare.
China has a vast territory, large population base and uneven medical standards
.
It is a very difficult task to carry out epidemiological investigations of rare diseases .
In recent years, the two teams of Professor Shi Fudong and Wang Yongjun from the National Neurological Diseases Clinical Medicine Research Center of Beijing Tiantan Hospital have collectively tackled key problems.
Using the database of the Chinese Hospital Quality Monitoring System (HQMS), the incidence of neuroimmune system diseases in China has been described for the first time through a series of big data analysis.
Rate map
.
In total, at least 27,500 people suffer from the above five neuroimmune diseases every year, an average of 75 people per day
.
The Hospital Quality Monitoring System (HQMS, Figure 1) is the direct reporting work of the National Health Commission's medical service supervision information network, and is the main basis for the performance appraisal of tertiary public hospitals across the country
.
HQMS uses unified data collection quality and interface standards to automatically connect the homepage information of inpatients
.
In view of the national coverage of HQMS and the unified disease code, there is a unique advantage in studying the incidence of rare diseases
.
The National Medical Quality Control Center for Neurological Diseases in Beijing Tiantan Hospital provides analytical support for the investigation of the incidence of rare diseases such as neuroimmunity
.
Figure 1 Data storage of the National Neurological Diseases Medical Quality Control Center (left, some researchers Zheng Pei, Li Xindian, Tian Decai and Dr.
Shi Fudong) and output interface (right: Dr.
Shi Fudong) Based on HQMS, Professor Shi Fudong’s team has completed major neuroimmune diseases Including multiple sclerosis, optic neuromyelitis spectrum diseases, myasthenia gravis, acute disseminated encephalomyelitis, and Guillain-Barré syndrome annual incidence, average hospitalization costs and other clinical indicators survey and report (Table 1)
.
Table 1 The incidence of major neuroimmune diseases in my country The research results on the incidence of neuroimmune diseases in China have filled the gap in the global epidemiological map
.
It is reported that Professor Shi Fudong’s team is currently studying the prevalence of such diseases, average length of stay, hospitalization expenses and other indicators.
The purpose is to provide core reference data for the country to further improve the medical security of such patients and the investment in new drug R&D of enterprises, and to better serve Provide scientific and precise medical services for patients with neuroimmune diseases
.
Since the end of 2018, Professor Shi Fudong has integrated the neuroimmunology team of Tianjin Medical University General Hospital and Beijing Tiantan Hospital to establish the Beijing-Tianjin Neuroimmune Center (Figure 2)
.
At present, the center has 30 neuroimmunologists, 10 full-time technicians, 6 doctoral supervisors, 7 master supervisors, 5 chief physicians, and 6 associate chief physicians
.
The center is full of talents, including Changjiang Scholars Distinguished Professors, Chief Scientists of the National Major Science and Technology Program (973), Beijing Strategic Scientists, and winners of the National Outstanding Youth Fund
.
For more than ten years, the team of Professor Fudong Shi has been unremittingly committed to innovating and improving the diagnosis and treatment strategies of neuroimmune diseases.
The clinical research results have provided Level I evidence for such diseases; the laboratory diagnostic technology with independent property rights has been developed and promoted; the first launch 7T ultra-high-resolution MRI scan of neuroimmune diseases; the first to start and enrich the drug modification treatment of neuromyelitis optica, multiple sclerosis, myasthenia gravis and other diseases in China, as well as blood purification treatment including plasma adsorption, for domestic diagnosis and treatment The most comprehensive neuroimmunological disease treatment center
.
Figure 2 Beijing-Tianjin Neuroimmune Team: Some members participating in the national epidemiological study of neuroimmune diseases will be in the campus stadium of Beijing Tiantan Hospital in the summer and autumn of 2021
.
.
Due to the abnormal activation of the immune system, this type of disease recognizes and attacks its own nervous tissues, resulting in a variety of complex neurological symptoms including blindness, paralysis, pain and paresthesias
.
A small number of patients will have difficulty breathing, even life-threatening
.
As the first cause of disability among young and middle-aged people, the course of this type of disease is protracted and repeated, causing heavy family and social burdens
.
As more and more immune-targeted drugs enter the market and medical insurance, the treatment of neuroimmune diseases ushered in the spring of our country
.
But we know that an important reference data for the country to formulate medical security policies and invest in disease research and development, the "morbidity rate" of diseases, that is, the basic question of how many people suffer from such diseases each year, is still a blank in our country, which has become a national issue.
Further use of these new drugs to better improve the barriers to these patients' medical services
.
On November 2, 2021, China published the incidence of Guillain-Barré syndrome in China for the first time in The Lancet Regional Health-Western Pacific (https:// /pii/S266660652100211X)
.
The article shows that the incidence of the disease in 31 provinces, autonomous regions and municipalities across the country is 0.
698 per 100,000, of which 0.
233 per 100,000 children and 0.
829 per 100,000 adults
.
Autoimmune diseases of the nervous system are relatively rare.
China has a vast territory, large population base and uneven medical standards
.
It is a very difficult task to carry out epidemiological investigations of rare diseases .
In recent years, the two teams of Professor Shi Fudong and Wang Yongjun from the National Neurological Diseases Clinical Medicine Research Center of Beijing Tiantan Hospital have collectively tackled key problems.
Using the database of the Chinese Hospital Quality Monitoring System (HQMS), the incidence of neuroimmune system diseases in China has been described for the first time through a series of big data analysis.
Rate map
.
In total, at least 27,500 people suffer from the above five neuroimmune diseases every year, an average of 75 people per day
.
The Hospital Quality Monitoring System (HQMS, Figure 1) is the direct reporting work of the National Health Commission's medical service supervision information network, and is the main basis for the performance appraisal of tertiary public hospitals across the country
.
HQMS uses unified data collection quality and interface standards to automatically connect the homepage information of inpatients
.
In view of the national coverage of HQMS and the unified disease code, there is a unique advantage in studying the incidence of rare diseases
.
The National Medical Quality Control Center for Neurological Diseases in Beijing Tiantan Hospital provides analytical support for the investigation of the incidence of rare diseases such as neuroimmunity
.
Figure 1 Data storage of the National Neurological Diseases Medical Quality Control Center (left, some researchers Zheng Pei, Li Xindian, Tian Decai and Dr.
Shi Fudong) and output interface (right: Dr.
Shi Fudong) Based on HQMS, Professor Shi Fudong’s team has completed major neuroimmune diseases Including multiple sclerosis, optic neuromyelitis spectrum diseases, myasthenia gravis, acute disseminated encephalomyelitis, and Guillain-Barré syndrome annual incidence, average hospitalization costs and other clinical indicators survey and report (Table 1)
.
Table 1 The incidence of major neuroimmune diseases in my country The research results on the incidence of neuroimmune diseases in China have filled the gap in the global epidemiological map
.
It is reported that Professor Shi Fudong’s team is currently studying the prevalence of such diseases, average length of stay, hospitalization expenses and other indicators.
The purpose is to provide core reference data for the country to further improve the medical security of such patients and the investment in new drug R&D of enterprises, and to better serve Provide scientific and precise medical services for patients with neuroimmune diseases
.
Since the end of 2018, Professor Shi Fudong has integrated the neuroimmunology team of Tianjin Medical University General Hospital and Beijing Tiantan Hospital to establish the Beijing-Tianjin Neuroimmune Center (Figure 2)
.
At present, the center has 30 neuroimmunologists, 10 full-time technicians, 6 doctoral supervisors, 7 master supervisors, 5 chief physicians, and 6 associate chief physicians
.
The center is full of talents, including Changjiang Scholars Distinguished Professors, Chief Scientists of the National Major Science and Technology Program (973), Beijing Strategic Scientists, and winners of the National Outstanding Youth Fund
.
For more than ten years, the team of Professor Fudong Shi has been unremittingly committed to innovating and improving the diagnosis and treatment strategies of neuroimmune diseases.
The clinical research results have provided Level I evidence for such diseases; the laboratory diagnostic technology with independent property rights has been developed and promoted; the first launch 7T ultra-high-resolution MRI scan of neuroimmune diseases; the first to start and enrich the drug modification treatment of neuromyelitis optica, multiple sclerosis, myasthenia gravis and other diseases in China, as well as blood purification treatment including plasma adsorption, for domestic diagnosis and treatment The most comprehensive neuroimmunological disease treatment center
.
Figure 2 Beijing-Tianjin Neuroimmune Team: Some members participating in the national epidemiological study of neuroimmune diseases will be in the campus stadium of Beijing Tiantan Hospital in the summer and autumn of 2021
.
